噻托溴铵联合福多司坦治疗支气管扩张症急性加重患者的临床效果及对炎性因子的影响

Clinical effects of tiotropium bromide combined with fudosteine in the treatment of patients with acute exacerbation of bronchiectasis and its influence on inflammatory factors

目的观察噻托溴铵联合福多司坦治疗支气管扩张症急性加重患者的临床效果及对炎性因子的影响。方法抽选2018年1月-2020年4月龙岩市第二医院收治的支气管扩张症急性加重患者86例,按随机数字表法将其分为常规组(实施常规对症治疗)和研究组(在常规对症治疗基础上实施噻托溴铵联合福多司坦治疗),每组43例。比较2组患者治疗前、治疗1个月后的炎性因子[超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)]水平、血气分析指标[氧分压(PaO_(2))、二氧化碳分压(PaCO_(2))、血氧饱和度(SaO_(2))]及气道传导率(Gaw)、气道阻力(Raw)、第1秒用力呼气容积(FEV1)。结果治疗1个月后,2组hs-CRP、IL-6、IL-8水平相较于治疗前均明显降低,且研究组低于常规组(P均<0.01);2组PaCO_(2)、Raw相较于治疗前下降,PaO_(2)、SaO_(2)和Gaw、FEV;相较于治疗前升高,且研究组上述指标降低或升高幅度大于常规组(P均<0.01)。结论噻托溴铵联合福多司坦治疗支气管扩张症急性加重期患者效果确切,能显著改善患者血气分析指标,降低炎性因子水平,提升患者的肺功能,有利于疾病的转归。

Objective To observe the clinical effect of tiotropium bromide combined with fudosteine in the treatment of patients with acute exacerbation of bronchiectasis and its influence on inflammatory factors. Methods A total of 86 patients with acute exacerbation of bronchiectasis admitted to the Second Hospital of Longyan from January 2018 to April 2020 were selected and divided into conventional group and study group according to the random number table method,with 43 cases in each group. The conventional group received conventional symptomatic treatment,and the study group received tiotropium bromide combined with fudosteine on the basis of conventional symptomatic treatment. Compared the inflammatory factors of the two groups before treatment and one month after treatment( hs-CRP,IL-6,IL-8),blood gas analysis indexes( Pa O_(2),Pa CO_(2),Sa O_(2)),airway conductivity( Gaw),airway resistance( Raw),forced expiratory volume in one second( FEV1).Results After 1 month of treatment,the levels of hs-CRP,IL-6,and IL-8 in the two groups were significantly lower than those before treatment,and the levels in the study group were lower than those in the conventional group( all P < 0. 01);The Pa CO_(2)and Raw levels of the two groups decreased compared to before treatment,Pa O_(2),Sa O_(2)and Gaw,FEV;levels increased compared to before treatment,and the above indicators of the study group decreased or increased more than the conventional group( all P < 0. 01). Conclusion Tiotropium bromide combined with fudosteine is effective in the treatment of patients with acute exacerbation of bronchiectasis. It can significantly improve the blood gas analysis indicators of the patients,reduce the level of inflammatory factors,and improve the lung function of the patients,which is beneficial to the outcome of the disease.